ES2097878T3 - Fijacion de p53 sobre el adn mediante una secuencia especifica. - Google Patents

Fijacion de p53 sobre el adn mediante una secuencia especifica.

Info

Publication number
ES2097878T3
ES2097878T3 ES92305333T ES92305333T ES2097878T3 ES 2097878 T3 ES2097878 T3 ES 2097878T3 ES 92305333 T ES92305333 T ES 92305333T ES 92305333 T ES92305333 T ES 92305333T ES 2097878 T3 ES2097878 T3 ES 2097878T3
Authority
ES
Spain
Prior art keywords
dna
wild
fixation
sequences
specific sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92305333T
Other languages
English (en)
Inventor
Bert Vogelstein
Kenneth W Kinzler
Michael I Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmagenics Inc
Johns Hopkins University
Original Assignee
Pharmagenics Inc
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27109289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2097878(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmagenics Inc, Johns Hopkins University filed Critical Pharmagenics Inc
Application granted granted Critical
Publication of ES2097878T3 publication Critical patent/ES2097878T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LAS SECUENCIAS ESPECIFICAS EN EL GENOMA HUMANO SON LOS LUGARES DE FUERTE UNION DE LA PROTEINA DE TIPO SALVAJE P53, PERO NO DE LAS FORMAS MUTANTES DE LA PROTEINA. ESTAS SECUENCIAS SE USAN EN PROCEDIMIENTOS DE DIAGNOSTICO PARA DETECTAR CELULAS EN LAS CUALES LA CANTIDAD DE P53 DE TIPO SALVAJE HA SIDO DISMINUIDA. LAS SECUENCIAS PUEDEN USARSE TAMBIEN PARA FILTRAR AGENTES QUE CORRIGEN LA PERDIDA DEL P53 DE TIPO SALVAJE EN EL DNA DE LAS CELULAS DEL CANCER.
ES92305333T 1991-06-14 1992-06-10 Fijacion de p53 sobre el adn mediante una secuencia especifica. Expired - Lifetime ES2097878T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71518291A 1991-06-14 1991-06-14
US07/860,758 US5362623A (en) 1991-06-14 1992-03-31 Sequence specific DNA binding by p53

Publications (1)

Publication Number Publication Date
ES2097878T3 true ES2097878T3 (es) 1997-04-16

Family

ID=27109289

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92305333T Expired - Lifetime ES2097878T3 (es) 1991-06-14 1992-06-10 Fijacion de p53 sobre el adn mediante una secuencia especifica.

Country Status (10)

Country Link
US (4) US5362623A (es)
EP (1) EP0518650B1 (es)
JP (1) JPH0678798A (es)
AT (1) ATE147512T1 (es)
AU (1) AU666479B2 (es)
CA (1) CA2070979C (es)
DE (1) DE69216478T2 (es)
DK (1) DK0518650T3 (es)
ES (1) ES2097878T3 (es)
GR (1) GR3022473T3 (es)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532220A (en) * 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
AU663702B2 (en) 1991-03-06 1995-10-19 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
WO1993020235A1 (en) * 1992-04-01 1993-10-14 The Johns Hopkins University School Of Medicine Methods of detecting mammalian nucleic acids isolated from stool specimen and reagents therefor
US5670330A (en) * 1992-09-29 1997-09-23 Mcgill University Anti-tumor agent assay using PKR
EP0675967A4 (en) * 1992-10-01 1999-04-28 Gen Hospital Corp Functional assay for tumor suppressor genes.
EP0633268B1 (en) * 1993-05-14 2004-07-28 Cancer Institute MDC proteins and DNAs encoding the same
US5659024A (en) * 1994-01-14 1997-08-19 The Burnham Institute Promotors that regulate the expression of genes involved in cell death
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US5693473A (en) * 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
PT699754E (pt) * 1994-08-12 2001-04-30 Us Health Metodo para diagnosticar uma predisposicao para cancro da mama e do ovario
US5753441A (en) * 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5573925A (en) * 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
US5721340A (en) * 1994-11-28 1998-02-24 The Wistar Institute Of Anatomy & Biology p53 proteins with altered tetramerization domains
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
WO1997007244A1 (en) * 1995-08-11 1997-02-27 The United States Of America, Represented By The ISOLATION OF AMPLIFIED GENES VIA cDNA SUBTRACTIVE HYBRIDIZATION
AU7127296A (en) 1995-09-18 1997-04-09 Novartis Ag Assay for identifying inhibitors of the interaction between proteins p53 and dm2
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
US5847083A (en) * 1996-08-21 1998-12-08 The Wistar Institute Of Anatomy And Biology Modified p53 constructs which enhance DNA binding
WO1997010843A1 (en) * 1995-09-22 1997-03-27 The Wistar Institute Of Anatomy And Biology Modified p53 constructs and uses therefor
ES2264145T3 (es) * 1995-11-30 2006-12-16 The Board Of Regents, The University Of Texas System Metodos y composiciones para el tratamiento de cancer.
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US6242212B1 (en) * 1996-02-09 2001-06-05 Thomas Jefferson University Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins
JPH09252783A (ja) * 1996-03-26 1997-09-30 Nippon Suisan Kaisha Ltd 腸炎ビブリオ検出のためのヌクレオチドおよびそれを用いた検出法
US5861249A (en) * 1996-04-23 1999-01-19 Cold Spring Harbor Laboratory Assays and reagents for identifying modulators of cdc25-mediated mitotic activation
US5830751A (en) * 1996-05-01 1998-11-03 The Johns Hopkins University Genetic assays and strains using human TP53
US5876711A (en) * 1996-05-31 1999-03-02 Onyx Pharmaceuticals, Inc. Methods and compositions for determining the tumor suppressor status of cells
US5858673A (en) * 1996-06-24 1999-01-12 Charlotte-Mecklenburg Hospital Authority Method for detecting prostate cells
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
US5744310A (en) * 1996-07-29 1998-04-28 The Burnham Institute Bax promoter sequence and screening assays for indentifying agents that regulate bax gene expression
US5827658A (en) * 1996-08-09 1998-10-27 The United States Of America As Reprsented By The Department Of Health And Human Services Isolation of amplified genes via cDNA subtractive hybridization
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6300077B1 (en) 1996-08-14 2001-10-09 Exact Sciences Corporation Methods for the detection of nucleic acids
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US6406857B1 (en) 1997-06-16 2002-06-18 Exact Sciences Corporation Methods for stool sample preparation
US6268136B1 (en) 1997-06-16 2001-07-31 Exact Science Corporation Methods for stool sample preparation
WO1999001763A2 (en) * 1997-07-02 1999-01-14 Board Of Regents, The University Of Texas System p53 AS A REGULATOR OF CELL DIFFERENTIATION
CA2214461A1 (en) * 1997-09-02 1999-03-02 Mcgill University Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53
US20020064792A1 (en) * 1997-11-13 2002-05-30 Lincoln Stephen E. Database for storage and analysis of full-length sequences
US6388062B1 (en) 1998-05-08 2002-05-14 The Wistar Institute Of Anatomy And Biology Modified p53 tetramerization domains having hydrophobic amino acid substitutions
US6429298B1 (en) 1998-10-13 2002-08-06 Board Of Regents, The University Of Texas System Assays for identifying functional alterations in the p53 tumor suppressor
DE19847779C1 (de) * 1998-10-16 2000-02-03 Deutsches Krebsforsch p53-Bindungsregionen
US6911307B1 (en) * 1998-12-08 2005-06-28 Proteus S.A. Method of detection in vitro of a target substance in a sample comprising the labelling of said substance with a reporter gene and with the sequences necessary for the expression of said reporter gene in vitro
US6280947B1 (en) 1999-08-11 2001-08-28 Exact Sciences Corporation Methods for detecting nucleotide insertion or deletion using primer extension
US6503718B2 (en) 1999-01-10 2003-01-07 Exact Sciences Corporation Methods for detecting mutations using primer extension for detecting disease
CA2362251C (en) 1999-02-25 2008-06-17 Exact Sciences Corporation Methods for preserving dna integrity
DE60029092T2 (de) 1999-04-09 2007-02-01 Exact Sciences Corp., Marlborough Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen
US6297013B1 (en) * 1999-06-24 2001-10-02 Dnab Diagnostics Inc. Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription
US6849403B1 (en) 1999-09-08 2005-02-01 Exact Sciences Corporation Apparatus and method for drug screening
US6586177B1 (en) 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
DE60043896D1 (de) * 1999-12-07 2010-04-08 Exact Sciences Corp Verfahren zum nachweis von lungenneoplasmen in fäkalen proben
US6919174B1 (en) 1999-12-07 2005-07-19 Exact Sciences Corporation Methods for disease detection
US6831155B2 (en) * 1999-12-08 2004-12-14 President And Fellows Of Harvard College Inhibition of p53 degradation
US6989239B2 (en) * 2001-06-20 2006-01-24 R.E.D. Laboratories, N.V./S.A. Methods for diagnosis and treatment of chronic immune diseases
US20040241653A1 (en) * 2001-12-31 2004-12-02 Elena Feinstein Methods for identifying marker genes for cancer
WO2003071252A2 (en) 2002-02-15 2003-08-28 Exact Sciences Corporation Methods for analysis of molecular events
JP4051327B2 (ja) * 2003-09-19 2008-02-20 新科實業有限公司 垂直磁気記録ヘッドおよびその製造方法、ならびに磁気記録装置
PL1799230T3 (pl) 2004-08-27 2013-05-31 Cyclacel Ltd Purynowe i pirymidynowe inhibitory CDK i ich zastosowanie do leczenia chorób autoimmunologicznych
US7981607B2 (en) 2004-08-27 2011-07-19 Esoterix Genetic Laboratories LLC Method for detecting recombinant event
US9109256B2 (en) 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
WO2007044071A2 (en) 2005-04-21 2007-04-19 Exact Sciences Corporation Analysis of heterogeneous nucleic acid samples
US20110236916A1 (en) 2010-03-26 2011-09-29 Mayo Foundation For Medical Education And Research Methods and materials for detecting colorectal neoplasm
US8470967B2 (en) * 2010-09-24 2013-06-25 Duke University Phase transition biopolymers and methods of use
JP2014519310A (ja) 2011-02-02 2014-08-14 エクザクト サイエンシーズ コーポレイション Ｄｎａメチル化のデジタル配列分析
ES2859645T3 (es) 2013-03-14 2021-10-04 Mayo Found Medical Education & Res Detección de neoplasia
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
WO2015066695A1 (en) 2013-11-04 2015-05-07 Exact Sciences Corporation Multiple-control calibrators for dna quantitation
US11286519B2 (en) 2013-12-11 2022-03-29 Accuragen Holdings Limited Methods and compositions for enrichment of amplification products
KR20240025725A (ko) 2013-12-11 2024-02-27 아큐라젠 홀딩스 리미티드 희귀 서열 변이를 검출하기 위한 조성물 및 방법
US11859246B2 (en) 2013-12-11 2024-01-02 Accuragen Holdings Limited Methods and compositions for enrichment of amplification products
EP4209600A1 (en) 2013-12-19 2023-07-12 Exact Sciences Corporation Synthetic nucleic acid control molecules
CN106460046A (zh) 2014-03-31 2017-02-22 梅奥医学教育和研究基金会 检测结直肠赘生物
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
US10030272B2 (en) 2015-02-27 2018-07-24 Mayo Foundation For Medical Education And Research Detecting gastrointestinal neoplasms
WO2016154530A1 (en) 2015-03-26 2016-09-29 Duke University Targeted therapeutic agents comprising multivalent protein-biopolymer fusions
WO2016160454A1 (en) 2015-03-27 2016-10-06 Exact Sciences Corporation Detecting esophageal disorders
WO2017024182A1 (en) 2015-08-04 2017-02-09 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
KR20250172724A (ko) 2015-08-31 2025-12-09 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 위 신생물 검출 방법
MX2018004284A (es) 2015-10-09 2018-05-16 Accuragen Holdings Ltd Metodos y composiciones para el enriquecimiento de productos de amplificacion.
EP3383994A4 (en) 2015-12-03 2019-08-28 Accuragen Holdings Limited METHOD AND COMPOSITIONS FOR FORMING LIGATION PRODUCTS
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
US10370726B2 (en) 2016-04-14 2019-08-06 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasia
US11078543B2 (en) 2016-04-14 2021-08-03 Mayo Foundation For Medical Education And Research Detecting pancreatic high-grade dysplasia
CN109511265B (zh) 2016-05-16 2023-07-14 安可济控股有限公司 通过链鉴定改进测序的方法
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
WO2018035170A1 (en) 2016-08-15 2018-02-22 Accuragen Holdings Limited Compositions and methods for detecting rare sequence variants
WO2018053201A1 (en) 2016-09-14 2018-03-22 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
EP3515928B1 (en) 2016-09-23 2026-01-28 Duke University Unstructured non-repetitive polypeptides having lcst behavior
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
CN110431241B (zh) 2017-02-28 2024-04-19 梅约医学教育与研究基金会 检测前列腺癌
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULUS SENSITIVE BIOPOLYMER NETWORKS
CN107656059B (zh) * 2017-09-26 2019-06-18 中南大学 一种用于p53蛋白的荧光检测剂及其制备方法和应用
JP7277460B2 (ja) 2017-11-30 2023-05-19 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ 乳癌の検出
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
US11203782B2 (en) 2018-03-29 2021-12-21 Accuragen Holdings Limited Compositions and methods comprising asymmetric barcoding
EP3788343B1 (en) 2018-04-30 2024-03-27 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
WO2019241290A1 (en) 2018-06-12 2019-12-19 Accuragen Holdings Limited Methods and compositions for forming ligation products
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
WO2020051541A1 (en) 2018-09-07 2020-03-12 Duke University Nanoparticulate drug delivery systems
US20200283843A1 (en) * 2019-03-04 2020-09-10 The Broad Institute, Inc. Methods and compositions for massively parallel variant and small molecule phenotyping
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0204922A3 (en) * 1985-05-28 1987-09-30 Abbott Laboratories Immunohistochemical assay for detection of a tumor-associated marker (p53)
US5447841A (en) * 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US4917999A (en) * 1986-09-02 1990-04-17 Miles Inc. Oligonucleotide probes for detection of α-amylase genes
US4994371A (en) * 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
EP0390323B2 (en) * 1989-03-29 2012-08-08 Johns Hopkins University Detection of loss of the wild-type p53 gene
NZ233255A (en) * 1989-04-11 1993-02-25 Chiron Corp Plasmodium cs protein analogues lacking one or more of the repeat epitopes, and containing at least one nonrepeat flanking epitope
US5068175A (en) * 1989-05-26 1991-11-26 Board Of Regents, The University Of Texas Sysem Method of detecting ras oncogene related malignancies
WO1992000311A1 (en) * 1990-06-27 1992-01-09 Princeton University Probes for detecting mutant p53
FI931268A7 (fi) * 1990-09-24 1993-04-21 Massachusetts Gen Hospital Seulontamenetelmiä
US5434257A (en) * 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5571903A (en) * 1993-07-09 1996-11-05 Lynx Therapeutics, Inc. Auto-ligating oligonucleotide compounds

Also Published As

Publication number Publication date
US5362623A (en) 1994-11-08
AU1820092A (en) 1992-12-17
EP0518650A2 (en) 1992-12-16
ATE147512T1 (de) 1997-01-15
DE69216478D1 (de) 1997-02-20
US5955263A (en) 1999-09-21
US20020164595A1 (en) 2002-11-07
CA2070979A1 (en) 1992-12-15
CA2070979C (en) 2006-01-03
US6245515B1 (en) 2001-06-12
EP0518650B1 (en) 1997-01-08
EP0518650A3 (en) 1993-01-20
DK0518650T3 (da) 1997-01-27
GR3022473T3 (en) 1997-05-31
US7087583B2 (en) 2006-08-08
DE69216478T2 (de) 1998-02-19
AU666479B2 (en) 1996-02-15
JPH0678798A (ja) 1994-03-22

Similar Documents

Publication Publication Date Title
TR200002355T2 (tr) 2-(Pürin-9-il)tetrahidrofüran-3,4-diol türevleri
ES2054878T3 (es) Expresion de la proapolipoproteina a-i humana.
ES2154661T3 (es) Preparados liquidos que contienen cyclosporin y procedimiento para su obtencion.
CY1105364T1 (el) Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης
DE59203666D1 (de) Medizinische Zange.
DE59006779D1 (de) Medizinische, insbesondere zahnmedizinische Einrichtung.
ATE232396T1 (de) Oxydiertes thymosin beta 4
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
DK0518650T3 (da) Sekvensspecifik DNA-binding med p53
SE8000435L (sv) N-bensylimidazoler med selektivt inhiberande verkan pa tromboxansyntetasenzymet jemte farmaceutiska beredningar innehallande sadana n-bensylimidazoler och sett for deras framstellning
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
DE59009354D1 (de) Zahnärztlicher Patientenstuhl.
ES2166900T3 (es) Derivados de ara-c.
MX169824B (es) Mejoras a cepillo dental con soltura lenta de desinfectante y agentes antibacterianos y metodo para la fabricacion del mismo
CY1109029T1 (el) Νουκλεϊνικο οξυ και αντιστοιχη πρωτεϊνη ονομαζομενη 85p1b3 χρησιμα στην αγωγη και τον εντοπισμο του καρκινου
DE68907635D1 (de) Loetmaterial fuer brillengestelle und brillengestelle, bei denen dieses loetmaterial verwendet ist.
DE69017366D1 (de) Endoskop mit austauschbarer Direktsicht-/Seitsichtbeobachtung.
ES2188802T3 (es) Vectores viricos de replicacion condicional y su uso.
IT1241123B (it) Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
DK76688D0 (da) Vaccine indeholdende f-proteinet fra aids-virus
IT7928015A0 (it) Derivato del paracetamol,procedimento per la sua preparazione e suo impiego nel campo terapeutico.
TR25921A (tr) PESTISID ETKINLIGI HAIZ PESTISID ÖZELLIKTE BISIKLOOKTANLAR,BUNLARI IHTIVA EDEN FORMüLASYONLAR VE HAZIRLANMALARINA MAHSUS USULLER.
ATE311886T1 (de) Verwendung einer zusammensetzung enthaltend 5- androsten-3beta,17alpha-diol
DE69718510D1 (de) Plasmid mit 2 oder mehreren sequenzkompetitoren und deren anwendung in kompetitiven pcr techniken

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 518650

Country of ref document: ES